Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aqueous humor cytokine levels after intravitreal ranibizumab or dexamethasone in diabetic macular edema
2014-005700-24Phase 4Completed
- Sponsor
- Department of Ophthalmology, Kepler University Hospital
- Start
- Jul 2015
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4 trial of ranibizumab and ozurdex in diabetic macular edema (DME) and diabetic retinopathy (DR) (2 arms), sponsored by Department of Ophthalmology, Kepler University Hospital. Primary endpoint: Change in aqueous humour cytokine levels. Started Jul 2015; status: completed.
02
Drugs
ranibizumabozurdex
03
Conditions
diabetic macular edema (DME)diabetic retinopathy (DR)
Beyond the preview
Go deeper on 2014-005700-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005700-24.